103 results about "Virus antigen" patented technology

The invention discloses a porcine epidemic diarrhea virus antigen fusion protein, a coding gene and a porcine epidemic diarrhea vaccine prepared from the porcine epidemic diarrhea virus antigen fusion protein. The method comprises the following steps: screening to obtain a homosensory sequence of the spike protein of the porcine epidemic diarrhea virus, and fusing the homosensory sequence with a monomeric porcine ferritin heavy chain subunit to obtain an antigen fusion protein; in order to improve the expression quantity or the titer of the antigen fusion protein, the obtained antigen fusion protein is subjected to sequence optimization and then subjected to single-site or multi-site mutation, and the expression quantity and the titer of the obtained mutant are remarkably improved. According to the invention, a recombinant protein is expressed by using a silkworm or AcMNPV-insect cell and other eukaryotic expression systems to obtain a self-assembled ferritin nanoparticle antigen for displaying an S protein antigen protein on the surface of a cage structure of porcine ferritin, and a vaccine prepared from the prepared nanoparticle antigen can induce a widely neutralized anti-porcine epidemic diarrhea virus antibody; the porcine epidemic diarrhea virus vaccine has the potential of becoming a universal porcine epidemic diarrhea virus vaccine with cross immune efficacy.

The present invention discloses a porcine Seneca virus neutralization liquid phase blocking ELISA kit, which comprises an effective amount of porcine Seneca virus antigen, an effective amount of porcine Seneca virus single domain antibody 1, an effective amount of porcine Seneca virus single domain antibody 2, and a matching detection reagent. The porcine Seneca virus antigen is porcine Seneca virus particles purified by sucrose density gradient centrifugation, and the particle size of the purified porcine Seneca virus particles is 20 to 30 nm. The amino acid sequence of the heavy chain variable region of the porcine Seneca virus single domain antibody 1 is shown in SEQ ID NO.1. The amino acid sequence of the heavy chain variable region of the porcine Seneca virus single domain antibody 2 is shown in SEQ ID NO.2. The kit of the present invention has the advantages of high efficiency, simplicity, sensitivity, stability, etc., has a good correlation with the traditional diagnostic method virus neutralization experiment, and is suitable for a wide range of applications.

The utility model relates to the field of antigen detection kits, and discloses an infectious bovine rhinotracheitis virus antigen detection kit which comprises a box body, a roller is rotatably connected to the bottom side in the box body, a clamping groove is formed in the upper side of the roller, a clamping pin is connected to the clamping groove in a clamping mode, and a placing table is fixedly connected to the upper side of the clamping pin. A plurality of swab placing grooves, an extraction tube placing groove and a detection card placing groove are respectively formed in the upper side of the placing table, the plurality of swab placing grooves, the extraction tube placing groove and the detection card placing groove are distributed in a circumferential array, and sampling swabs are arranged on the inner sides of the plurality of swab placing grooves; according to the utility model, a plurality of groups of sampling swabs, sample extraction tubes and antigen detection cards which are distributed in a circumferential array manner are placed on the placement table, so that when sampling personnel go to cattle for sampling one by one, the sampling personnel can rotate to detection materials such as the next group of antigen detection cards and the like only by pressing down the push rod and switching the angle of the placement table, and the operation is convenient and the use is simple.

The invention relates to the technical field of immunodetection, and discloses a bovine nodular skin disease virus chimeric antigen and application thereof in an ELISA (enzyme-linked immuno sorbent assay) detection kit. According to the chimeric antigen, a gene of a dominant region of a bovine nodular skin disease virus antigen is selected to design a chimeric antigen gene, meanwhile, sequence optimization is performed, a chemical synthesis method is used for synthesizing a coding gene of the chimeric antigen of the bovine nodular skin disease virus, and then the chimeric antigen is obtained in a prokaryotic expression mode. An ELISA antibody detection kit developed on the basis of the chimeric antigen has extremely high sensitivity and specificity, can rapidly and specifically detect bovine nodular skin disease virus antibodies in serum, is suitable for monitoring and checking the nodular skin diseases of cattle in large-scale breeding, and has relatively high practical value.

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different serotypes of foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the different serotypes of foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum multivalent vaccine for foot-and-mouth disease.

The present invention relates to the field of biomedicine, and particularly to a T cell receptor and its preparation method and use. The T cell receptor EBV-TCR of the present invention comprises a variable region of the TCRα chain and a variable region of the TCRβ chain; the variable region of the TCRα chain contains peptide segments CDRα1, CDRα2, and CDRα3; the variable region of the TCRβ chain contains peptide segments CDRβ1, CDRβ2, and CDRβ3; the amino acid sequence of CDRα3 is as shown in SEQ ID NO.7, and the amino acid sequence of CDRβ3 is as shown in SEQ ID NO.3. The TCR of the present invention has high specificity, and binding to T cells can significantly activate cytokine release, providing a solid theoretical and experimental basis for the development of TCR-T therapy targeting Epstein-Barr virus antigens.

The invention relates to methods and kits for detecting a virus, e.g., a respiratory virus such as a coronavirus, in a biological sample. The invention also relates to methods and kits for detecting and / or quantifying biomarkers, e.g., antibody biomarkers against a viral antigen; inflammatory and / or tissue damage response biomarkers; and / or extracellular vesicles in response to a viral infection.

The invention relates to the technical field of virus antigens, and particularly discloses an inactivation method for improving the recovery rate of enterovirus antigens. The method disclosed by the invention specifically comprises the following steps: adding a protective agent with the final concentration of 50-250 [mu] g / ml into purified enterovirus liquid; after fully and uniformly mixing, stirring and incubating the mixed solution; the protective agent is prepared by mixing TritionX-100, arginine and lysine; the incubation temperature is 25-40 DEG C, and the incubation time is 4-12 hours; then adding a formaldehyde solution until the final concentration is 180-220 mu g / ml, and inactivating for 68-76 hours under the condition that the temperature is 35-39 DEG C, so as to obtain an inactivated vaccine; and finally, washing and filtering the inactivated solution to remove TritionX-100 and formaldehyde in the sample. According to the technical scheme, the recovery rate of the antigen in the inactivation solution is greatly improved, and the residual quantity of TritionX-100 and formaldehyde is small.

The invention relates to a linear covalent closed DNA vaccine, which comprises a plasmid vector containing an IHNV virus antigen expression unit, the sequence of the antigen expression unit is shown as SEQ ID NO.1, and the DNA structural form is a linear terminal covalent closed form. The invention also relates to a preparation method and application of the linear covalent closed DNA vaccine. Compared with a traditional DNA vaccine, the linear covalent closed DNA vaccine has no redundant bacterium source nucleic acid sequence, and has good safety and effectiveness for preventing and treating infectious hematopoietic necrosis of rainbow trout.

The invention relates to the technical field of genetic engineering, in particular to a self-assembled protein cage nanoparticle epitope insertion site and application thereof in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between the 124 -125 amino acid of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 124 -125 amino acid is replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.

The invention discloses an EB (Epstein-Barr) virus antigen with chimeric design and application thereof. The EB virus chimeric antigen provided by the invention is reasonably designed on the basis of structural biology, gL, gH and gp42 proteins of the EB virus are connected through a linker, and the chimeric designed antigen stably presents antigen epitopes of the three proteins at the same time, so that the production amplification process and quality control can be simplified while the vaccine immunogenicity is improved. The EB virus chimeric antigen can be used independently or in combination with other antigens, has high immunogenicity when being used as a vaccine or a vaccine component, can induce an immunized animal to generate a high-level neutralizing antibody, can be used for preparing a vaccine for preventing or treating EB virus infection, and can also be used as a reagent for detecting EB virus.

The present invention discloses a neutralizing monoclonal antibody against Epstein-Barr virus gB antigen and its application. The antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises heavy chain CDR-H1 shown in SEQ ID NO:15; heavy chain CDR-H2 shown in SEQ ID NO:16; and heavy chain CDR-H3 shown in SEQ ID NO:17. The light chain variable region comprises light chain CDR-L1 shown in SEQ ID NO:18; light chain CDR-L2 shown in SEQ ID NO:19; and light chain CDR-L3 shown in SEQ ID NO:20. The antibody in the present invention can specifically recognize Epstein-Barr virus gB antigen and has a good neutralizing effect, so that various expression vectors and transformants can be developed based on the antibody, and thus can be effectively used for the detection, prevention and treatment of Epstein-Barr virus.

The invention relates to a detection kit for nasopharynx cancer diagnosis and screening, which comprises an immunochromatography detection card, and the immunochromatography detection card comprises a reagent for detecting EB virus antigen and antibody through a colloidal gold labeling method. The invention also relates to application of the detection card and the EB virus antigen-antibody in preparation of a detection kit or a detection card for nasopharynx cancer diagnosis and screening.

The present invention relates to the field of biomedicine technology, and specifically discloses an mRNA based on the CP protein gene of fish nervous necrosis virus, a vaccine, and a preparation method and application thereof. The present invention provides an mRNA of fish nervous necrosis virus, the nucleotide sequence of which is shown in SEQ ID NO: 1, and the structure includes a 5' untranslated region, a signal peptide sequence, an NNV virus antigen coding region, a 3' untranslated region and polyA. The mRNA vaccine contains the ORF sequence of the capsid protein CP gene that is resistant to NNV virus infection. The results of animal safety tests on the fish nervous necrosis virus mRNA vaccine prepared by the present invention show that the vaccine is safe and effective, and is convenient and simple to use clinically, and has broad application prospects in the prevention and control of viral nervous necrosis in marine cultured fish.

The invention belongs to the technical field of poultry disease prevention and treatment, and discloses application of a rhizoma kaempferiae extract in preparation of a medicine for resisting avian infectious bronchitis virus. The rhizoma kaempferiae extract is prepared by taking rhizoma kaempferiae as a raw material and ethanol as an extraction solvent through extraction, filtration and concentration. Experimental results show that the rhizoma kaempferiae extract has no obvious toxicity to chick embryos within a certain dosage range; after the chicken embryo is infected with the infectious bronchitis virus, the survival rate of the chicken embryo can be improved by treating the chicken embryo with different doses of the rhizoma kaempferiae extract, and the rhizoma kaempferiae extract can reduce the virus antigen expression level and virus copy number in the liver tissue and allantoic fluid of the chicken embryo, so that the chicken embryo has prevention and treatment effects on infectious bronchitis virus infection. The rhizoma kaempferiae extract has the advantages of easily available raw materials, simple process and low cost, and is suitable for popularization and application.

This invention discloses an oral vaccine against carp spring viremia virus, its preparation method, and its application. The oral vaccine is constructed by linking a carp spring viremia virus antigen protein and a Yellow River carp defensin protein via a flexible linker to form a fusion protein, which is then expressed in *E. coli* and enriched using a biological vector. The gene sequence encoding this fusion protein includes a truncated fragment of the carp spring viremia virus antigen protein gene (64-1389 bp), a fragment of the Yellow River carp defensin protein gene (70-201 bp without the signal peptide), and a flexible linker fusion gene connecting the two gene fragments. Compared with previously reported anti-SVCV vaccines, the oral vaccine against carp spring viremia virus prepared in this invention does not harm the fish during the entire immunization process, is simple to operate, safe and stable, and has a higher protection rate. Therefore, this oral vaccine provides broad prospects for the prevention and control of carp spring viremia.

The invention provides a linear epitope of an African swine fever virus CP312R protein. The amino acid sequence of the linear epitope is SEQ ID NO: 1 or SEQ ID NO: 2. The antigen epitope polypeptide provided by the invention has good antigen specificity and immunoreactivity. The polypeptide can be efficiently combined with an African swine fever virus specific antibody, background interference is low, cross reaction is small, and detection sensitivity and accuracy are remarkably improved. By using the polypeptide as a coating antigen in immunodetection methods such as ELISA or colloidal gold immunochromatography, rapid and accurate detection of ASFV infection can be realized, and the detection result is stable and reliable. Compared with a traditional whole virus antigen or a crude extract antigen, the epitope polypeptide has the advantages of being simple and convenient to prepare, small in batch difference, high in safety and the like, and is suitable for ASFV serological monitoring and diagnosis application.

This application relates to the technical field of detection kits, and discloses an influenza virus antigen detection kit, which includes a box body, a cover plate, a handle, a detection platform, a placement groove opened at the top of the detection platform, and a detection strip placed in the placement groove. A driving device for driving the movement of the detection platform is installed in the box body. The driving device includes two first vertical grooves respectively opened on the inner walls of both sides of the box body, two first guide rods respectively fixed to the two first vertical grooves, and two sliding sleeves respectively slidably connected to the two first guide rods; the two sliding sleeves are respectively fixed to both sides of the detection platform. A first through hole is opened on one side of one first vertical groove, a first rack is slidably connected in the first through hole, and one of the sliding sleeves is fixed to one side of the first rack. A first gear is sleeved and fixed on the rotating shaft, and the first gear meshes with the first rack; a limiting mechanism for limiting the first rack is installed on the side wall of the first through hole. This application is convenient for testers to move and carry.

The invention provides a monoclonal antibody 3G1 capable of specifically recognizing CV-A5 virus and having neutralizing activity and application of the monoclonal antibody 3G1. The monoclonal antibody is prepared from a CV-A5 virus antigen immunized mouse and splenocytes of the mouse through a cell fusion technology, and amino acid sequences of three CDR regions of a heavy chain variable region of the monoclonal antibody sequentially comprise sequences as shown in SEQ ID NO.1-3; the amino acid sequences of the three CDR regions of the light chain variable region sequentially comprise sequences as shown in SEQ ID NO.4-6. The monoclonal antibody can be specifically combined with a CV-A5 virus, and is not combined with enteroviruses such as EV-A71, CV-A10, CV-A6, CV-A16 and the like. The monoclonal antibody targets conformational epitopes, has neutralizing activity, can specifically recognize CV-A5 viruses, is an ideal CV-A5 antigen detection antibody, and is beneficial to acceleration of the research and development process of hand-foot-mouth multivalent vaccines containing CV-A5 pathogens.

The present invention discloses a DC cell-based bifunctional nanobody, its construction method and application. The bifunctional nanobody is obtained by connecting a DC cell-based target protein-specific nanobody and a gene encoding a virus antigen-specific nanobody with a particle size of less than 150 nm through a linker element to obtain a target gene fragment and then recombinantly expressing the target protein. The technical means adopted in the present invention is universal, and specific nanobodies can be screened for different pathogens to construct corresponding porcine DC-targeted bifunctional nanobodies, which can be extended to other porcine vaccine antigens. The operation is simple, efficient, and time-consuming, and the bifunctional nanobody is relatively clear in design and structure, easy to be efficiently produced using a microbial genetic engineering system, with low manufacturing cost and good stability. The bifunctional nanobody can be used after incubation with the antigen, which is simple and easy to perform, more in line with the actual veterinary clinic, and convenient for popularization and application.

The invention belongs to the field of virus detection and diagnosis, and relates to an anti-AAV8 monoclonal antibody as well as a preparation method and application thereof. The invention provides an anti-AAV8 rabbit monoclonal antibody, and amino acid sequences of a heavy chain variable region and a light chain variable region of the anti-AAV8 rabbit monoclonal antibody. The anti-AAV8 rabbit monoclonal antibody provided by the invention can be specifically combined with VLP of AAV8, and can be used for detecting an AAV virus antigen. The anti-AAV8 monoclonal antibody provided by the invention provides an effective detection tool for AAV8 detection in a gene therapy vector research and development process and AAV8 detection in basic scientific research.

The present disclosure is directed to antibodies binding to and neutralizing henipavirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a henipavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and (b) detecting henipavirus in said sample by binding of said antibody or antibody fragment to a henipavirus antigen in said sample.

The invention relates to the technical field of genetic engineering, in particular to identification of a new insertion site of a self-assembled protein cage nanoparticle antigen epitope and application of the new insertion site in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between 62nd-63rd amino acids of an Encapsulin protein fragment after amino acid sequence modification, and / or the 62nd-63rd amino acids are replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.

The application discloses an influenza virus universal nanoparticle vaccine and a preparation method thereof. The application designs an influenza virus antigen by using an influenza virus matrix protein 2 extracellular domain (M2e) and hemagglutinin (HA), and forms a trimer structure by fusing a foldon motif at the C terminal of the antigen. On this basis, the application prepares an influenza virus antigen multimeric complex through a GvTagOpti / SdCatcher system, and prepares the influenza virus universal nanoparticle vaccine which can be inoculated through the respiratory system and has good immunoprotective effect by taking the obtained multimeric complex as an immunogen. The nanoparticle vaccine disclosed by the application not only has good immunoprotective effect and can prevent infection of different subtypes of influenza viruses after inoculation, but also has a simple preparation method, high safety and can be quickly applied to clinical trials.

The invention belongs to the field of virus detection and diagnosis, and relates to a monoclonal antibody for resisting various serotype AAV capsid proteins as well as a preparation method and application of the monoclonal antibody. The invention provides a rabbit monoclonal antibody for resisting various serotype AAV capsid proteins, and amino acid sequences of a heavy chain variable region and a light chain variable region of the rabbit monoclonal antibody. The rabbit monoclonal antibody for resisting various serotype AAV capsid proteins provided by the invention can be specifically combined with various serotype AAV capsid proteins VP1, VP2 and VP3, and can be used for detecting AAV virus antigens. The monoclonal antibody for resisting various serotype AAV capsid proteins provided by the invention provides possibility and convenience for the research and development process of gene therapy vectors and the detection of AAV in basic scientific research.

The invention belongs to the technical field of nano-antibodies, and particularly relates to a nano-antibody for resisting H1N1 influenza virus NA protein as well as a preparation method and application of the nano-antibody. The method comprises the following steps: by taking A / Puerto Rick / 8 / 34 (H1N1) influenza virus as a research object, purifying and inactivating the influenza virus through sucrose density gradient centrifugation, immunizing alpaca by taking the influenza virus as an immunogen, and screening by utilizing a phage display technology to obtain a high-affinity spectral anti-avian influenza virus NA protein nano antibody. Animal experiments show that the nano antibody has a good prevention effect when acting on A / Puerto Radio / 8 / 34 (H1N1) influenza virus infected C57 mice. Through preparation of the anti-influenza virus NA protein nano antibody, not only is a material provided for development of an H1N1 influenza virus diagnostic reagent, but also a thought is provided for identification of H1N1 subtype influenza virus epitope and vaccine design.

The invention relates to a respiratory syncytial virus antigen detection kit, and relates to the technical field of biomedical detection, the respiratory syncytial virus antigen detection kit comprises a respiratory syncytial virus antigen detection reagent strip, the reagent strip comprises a sample pad, a colloidal gold conjugate pad and a nitrocellulose membrane which are connected in sequence, the colloidal gold combination pad is coated with a colloidal gold labeled nano antibody which is specifically combined with the respiratory syncytial virus, and the nano antibody comprises a CDR sequence as shown in SEQ ID NO: 2-4. The kit provided by the invention has the effects of high detection sensitivity, good specificity and short detection time.

The present invention relates to the field of biomedicine technology, and specifically discloses a circular mRNA vaccine for marine farmed fish, a preparation method thereof, and an application thereof. The circular mRNA in the present invention includes an IRES untranslated region, a signal peptide sequence, and an NNV virus antigen coding region connected in sequence; in the preparation process, a DNA template with a T7 promoter is first synthesized by a chemical method, and T7 RNA transcription is performed using the DNA template. The transcribed RNA is adenylated, and then circularized and connected by T4 RNA enzyme 2 to generate circular RNA, and finally purified by ethanol precipitation to obtain NNV-B1 circular mRNA. The NNV-B1 circular mRNA vaccine prepared by the present invention has been shown by the results of the animal safety test to be safer and more effective, convenient and simple to use clinically, and has broad application prospects in the prevention and control of viral neuronecrosis.

The invention relates to a sample treatment liquid for respiratory virus antigen detection and a preparation method thereof. The sample treatment liquid comprises a phosphate buffer solution, 0.05-0.5 g / L of sodium caseinate, 1-20 g / L of bovine serum albumin, 10-50 mL / L of a surfactant, 1-10 g / L of guanidine hydrochloride, 3.72-37.2 g / L of an ethylene diamine tetraacetic acid disodium salt diaqueous solution, 1-5 mL / L of a CL preservative, 1-5 mL / L of a BND bacteriostatic agent and 900-988 mL / L of sterile deionized water. The method has the advantage of good sample stability.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.